- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02842125
Safety and Efficacy of Intra-Arterial and Intra-Tumoral Ad-p53 With Capecitabine (Xeloda) or Anti-PD-1 in Liver Metastases of Solid Tumors and Recurrent Head and Neck Squamous Cell Cancer
May 30, 2020 updated by: MultiVir, Inc.
Phase 1/2 Evaluation of Adenoviral p53 (Ad-p53) in Combination With Capecitabine (Xeloda) or Anti-PD-1 in Patients With Unresectable Liver Metastases of Colorectal Carcinoma(CRC) and Other Solid Tumors, Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) and Primary Hepatic Cancers With Known Disease Progression on Standard Therapy
This is a Phase 1/2 study of the combination of Ad-p53 administered intra-arterially in combination with oral metronomic capecitabine or pembrolizumab in patients with unresectable, refractory liver metastases of colorectal carcinoma (CRC) and other solid tumors, including primary hepatocellular carcinoma (HCC).
A third arm will study the intra-tumoral injection of Ad-p53 combined with nivolumab infusions in recurrent head and neck squamous cell cancer (HNSCC).
This safety study has a standard 3+3 design for arms A and B; .HNSCC will be placed in a single dosing cohort.
The Maximum Tolerated Dose (MTD) will be determined as well for intra-arterial infusions, and the entire study will determine the general efficacy using RECIST 1.1 and Immune-Related Response Criteria.
Safety will be followed using the CTCAE listings for adverse events.
Study Overview
Status
Terminated
Intervention / Treatment
Detailed Description
This is a Phase 1/2 study split into 3 arms.
Arm A will follow the combination of Ad-p53 administered intra-arterially in combination with oral metronomic capecitabine while Arm B follows the intra-arterial administration of Ad-p53 combined with pembrolizumab, both in patients with unresectable, refractory liver metastases of colorectal carcinoma (CRC) and other solid tumors, including primary hepatocellular carcinoma (HCC).
Arm C will follow the combination of intra-tumoral injections of Ad-p53 and nivolumab infusions.
Arms A and B have a standard 3+3 design, with dosing following the initial cohort determined by MTD and DLT criteria as well as safety and tolerance.
Arm C will be a single dosing cohort followed for safety and efficacy.
All patients will be followed for adverse events and preliminary efficacy.
In Arms A and B, the Maximum Tolerated dose (MTD) will be determined.
All patients will be followed for general safety and preliminary efficacy using RECIST 1.1 and Immune-Related Response Criteria.
CEA levels will also be followed for patients with metastatic colo-rectal cancer.
Biomarker testing of archival or fresh tissue is performed during the study.
In Arms A and B, patients will undergo a maximum of 2 8-week cycles, with scans every 8 weeks.
For Arm B, patients will undergo a maximum of 3 28-day Cycles.
All patients will continue on the background therapy for any additional cycles.
No additional biopsies are planned following Screening.
Enrollment will be up to 24 patients.
Study Type
Interventional
Enrollment (Actual)
4
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Texas
-
Houston, Texas, United States, 77030
- MD Anderson Cancer Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Signed informed consent
- Male or female, age 18 or above, who agree to use barrier contraception throughout the study. Females of child-bearing potential must be non-pregnant and non-lactating throughout the study.
- Histologically or cytologically confirmed solid tumors or hepatocellular carcinoma with known disease progression.
- Each patient entered on the study must have disease that is evaluable for response using RECIST 1.1 criteria with a minimum size of 1 cm by CT/MRI or physical examination
- Carcinoma patients in Arm A or Arm B must have received at least 1 prior regimen of standard of care systemic antitumor therapy for their metastatic disease and experienced tumor progression within 3 months after the last prior administration of the therapy or experienced unacceptable toxicity to these treatments.
- Subjects in Arm A and Arm B should have measurable CT evidence of liver metastases or liver lesions that are not treatable by surgical resection or local ablation in consultation with hepatobiliary specialist.
- The maximum tumor diameters for each Cohort for both Arm A and Arm B should achieve a dose of approximately 1x1011 viral particles (vp)/cm3 of tumor volume. (see Table 1). Please refer to Table for calculating tumor volume.
- ECOG Performance Status 0 - 1
- Either no brain metastases or irradiated stable brain metastases
- Life expectancy at least 3 months
- No prior autologous or allogeneic organ or tissue transplantation
- PT/international normalized ratio (INR) ≤ULN; aPTT ≤ULN.
- ANC ≥1500 cells/mm3
- Platelet count ≥100,000 cells/mm3
- Hemoglobin ≥9.0 g/dL
- Creatinine <2.0 mg/dL or creatinine clearance ≥50 mL/min
- Total bilirubin <1.5 x ULN
- AST and ALT <3.0 x ULN
- Alkaline phosphatase ≤5 x ULN
- Negative pregnancy test in women of childbearing potential
- Fertile patients must use effective contraception
- No non-approved investigational agents or procedures ≤4 weeks of study entry
- Patients with PRIMARY HEPATIC CANCER must have an undetectable viral load for Hepatitis B and C.
- Patients with Primary Hepatic Cancer have not recently been treated with antivirals.
- Troponin blood level within normal limits.
- Favorable biomarker profile defined by either wild type p53 gene sequence or less than 20% p53 positive tumor cells by immunohistochemistry
- Echocardiogram with normal ejection fractions
- Normal lung oxygen saturation by pulse oximeter, as determined by the Principal Investigator based on patient history and status.
Arm C patients must have loco-regional recurrent head and neck squamous cell carcinoma (HNSCC), excluding endolaryngeal recurrence, meeting the following criteria:
- Tumor progression within 6 months of platinum-based chemotherapy
- All HNSCC lesions should be in the head and neck region and suitable for intra-tumoral injection
- The total sum of Ad-p53 Injection Doses (mL) based upon the tumor volumes shown in Table 2 should be less than or equal to 25 mL as the MTD of Ad-p53 is 2.5 x1013 vp/treatment day.
Exclusion Criteria
- Subjects must not be candidates for hepatic surgery or locoregional therapy of liver tumors with curative intent.
- Liver tumors must not be estimated to invade approximately more than one-third of the liver.
- Liver tumor-directed therapy, hepatic surgery, antibody-based therapy, or immunotherapy must not have been performed < 28 days, chemotherapy < 21 days, and targeted small molecule therapy or hormonal therapy < 14 days prior to enrollment. No radiation to tumor sites during the last 4 weeks.
- No macroscopic intra-vascular invasion by tumors of the main portal vein, hepatic vein or vena cava.
- Chronic liver dysfunction prior to development of liver metastases (Child-Pugh C or greater).
- Active alcohol dependence
- Prior radiation performed to areas of measurable disease ≤ four weeks of study entry unless there is documented evidence of disease progression.
- Use of systemic anti-cancer therapy ≤ 4 weeks, or six weeks if the systemic therapy contains a nitrosourea or mitomycin C.
- Neuropathy (≥grade 2 CTCAE)
- History of allergic reactions to any components of the treatments
- Prior additional malignancy within 2 years except for non-melanoma skin cancer, carcinoma in situ of the breast, oral cavity or cervix.
Severe, active comorbidity, including any of the following:
- Active clinically serious infection requiring intravenous antibiotics at the time of study entry (CTCAE Grade 2)
- Hepatic insufficiency not due to tumor resulting in clinical jaundice or bilirubin >1.5 x ULN and/or coagulation defects
- Thrombotic or embolic event within the last 6 months including portal vein thrombosis
- Must not require concomitant treatment with anticoagulants
- QTcb >470 ms
- Bleeding or evidence or history of clinically significant bleeding diathesis or coagulopathy within the last 3 months
- Uncontrolled hypertension on anti-hypertensive medication (systolic blood pressure >150 mmHg or diastolic blood pressure >95 mmHg)
- Must not have been diagnosed with autoimmune disease or be immunosuppressed
- Patients with non-hepatocellular carcinoma must not have acute or chronic hepatitis B or hepatitis C infection
- Known significant immunodeficiency due to underlying illness (e.g. HIV/AIDS) and/or immunosuppressive medication including high-dose corticosteroids.
- Severe bleeding, hemoptysis, gastrointestinal hemorrhage, CNS bleeding, clinically significant hemorrhage or vaginal bleeding during the last 6 months
- Subjects must not have evidence of pneumonitis or inflammatory lung disease on CT scan and x-ray
- Chronic treatment for more than 6 months with systemic corticosteroids at doses above 10 mg prednisolone or equivalent before study entry
- Psychological, familial, sociological or geographical or other condition which in the opinion of the investigator would not permit study follow-up or other compliance with the study protocol.
- Subjects must not have tumors adjacent to vital structures such as carotid arteries.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NON_RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Ad-p53 with Xeloda 33.3% of patients
Up to 12 patients, in 3+3 cohorts, all patients treated with Intra-arterial Ad-P53 once weekly, dosing dependent on DLT and MTD findings, and daily metronomic Xeloda (capecetabine), at a dose of 625 mg/m2 BID continuously.
|
Adenoviral Investigational Product Ad-P53 to treat metastases using an intra-arterial catheter, with oral metronomic capecitabine
Oral metronomic chemotherapeutic agent
Other Names:
|
EXPERIMENTAL: Ad-p53 with Keytruda 33.3% of patients
Up to 12 patients, in 3+3 cohorts, all patients treated with Intra-arterial Ad-P53 once weekly, dosing dependent on DLT and MTD findings, and infusions of pembrolizumab every 3 weeks.
|
Adenoviral Investigational Product Ad-P53 to treat metastases using an intra-arterial catheter, with oral metronomic capecitabine
Antineoplastic, Monoclonal Antibody; PD-1/PD-L1 Inhibitors
Other Names:
|
EXPERIMENTAL: Ad-p53 with Opdivo 33.3% of patients
Up to 12 patients treated with intra-tumoral Ad-P53 3 times week 1 of each cycle, dose determined by tumor size, in combination with IV nivolumab (Opdivo) 480 mg, every 4 weeks.
|
Adenoviral Investigational Product Ad-P53 to treat metastases using an intra-arterial catheter, with oral metronomic capecitabine
Antineoplastic, Monoclonal Antibody; PD-1/PD-L1 Inhibitors
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety assessed by CTCAE
Time Frame: Screening to 30-days following Final Treatment (approximately 22 weeks)
|
Incidence of treatment-emergent and treatment-related adverse events (all AEs, laboratory AEs, SAEs and Fatal AEs, in accordance with the CTCAE
|
Screening to 30-days following Final Treatment (approximately 22 weeks)
|
Incidence of dose-limiting toxicities (DLTs)
Time Frame: Day 1 to 30-days Following Last Treatment (approximately 21 weeks)
|
To evaluate the safety, as assessed by the incidence of dose limiting toxicities, of the combination of Ad-P53 and Xeloda or Ad-p53 and Keytruda
|
Day 1 to 30-days Following Last Treatment (approximately 21 weeks)
|
Determination of maximum-tolerated dose (MTD)
Time Frame: Day 1 to 30 days following Final Treatment (Approximately 21 Weeks)
|
Determination of maximum tolerated dose (MTD) by review of DLTs, of the combination of Ad-p53 and Xeloda or Ad-p53 and Ketruda
|
Day 1 to 30 days following Final Treatment (Approximately 21 Weeks)
|
Progression-Free Survival (PFS) of patients using RECIST 1.1
Time Frame: Time Frame: Day 1 to progression through end of study, approximately 18 months
|
PFS in patients treated with Ad-p53 and nivolumab determined by review of scans every 8 weeks for disease progression in accordance with RECIST 1.1.
Scans are read locally but kept for possible central review.
Scans are done every 8 weeks.
Sites will review questionable findings on scans with Immune Related Response Criteria (irRC) [Wolchok 2009].
|
Time Frame: Day 1 to progression through end of study, approximately 18 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression-Free Survival (PFS) of patients using RECIST 1.1
Time Frame: Day 1 to progression through end of study, approximately 2 years
|
PFS determined by review of scans every 8 weeks for disease progression in accordance with RECIST 1.1 in patients treated with Ad-p53 and either Xeloda or Keytruda.
Scans are read locally but kept for possible central review.
Scans are done every 8 weeks.
|
Day 1 to progression through end of study, approximately 2 years
|
Efficacy determined by Immune Related Response Criteria (irRC) [Wolchok 2009]
Time Frame: Day 1 of Treatment through 30-days following last treatment (20 weeks)
|
Efficacy will be determined by review of the irRC (Immune-Related Response Criteria.
Patients will undergo scanning every 8 weeks for the duration of the study, with evaluation of the scans in accordance with the Immune Related Response Criteria, including confirmation of disease progression with a scan 4 weeks after noted per RECIST criteria.
|
Day 1 of Treatment through 30-days following last treatment (20 weeks)
|
Efficacy as determined by biomarker testing and immunohistochemistry testing
Time Frame: Day 1 of Treatment to End of Study (approximately 18 months)
|
Efficacy endpoints will be correlated with central biomarker testing for PDL-1, PD-2, as well as central biomarker testing for immune cell infiltrates and tumor mutational burden biomarkers in exploratory analyses, through Cancer Genetics, Inc.
|
Day 1 of Treatment to End of Study (approximately 18 months)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
November 20, 2018
Primary Completion (ACTUAL)
May 8, 2020
Study Completion (ACTUAL)
May 8, 2020
Study Registration Dates
First Submitted
July 1, 2016
First Submitted That Met QC Criteria
July 19, 2016
First Posted (ESTIMATE)
July 22, 2016
Study Record Updates
Last Update Posted (ACTUAL)
June 2, 2020
Last Update Submitted That Met QC Criteria
May 30, 2020
Last Verified
May 1, 2020
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- MultiVir Ad-p53-001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Recurrent Head and Neck Cancer
-
UNICANCERCompletedRecurrent Head and Neck Cancer | Metastatic Head and Neck CancerFrance
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.CompletedRecurrent Head and Neck Cancer | Metastatic Head and Neck CancerChina
-
Merck Sharp & Dohme LLCCompletedRecurrent Head and Neck Cancer | Metastatic Head and Neck Cancer
-
Dana-Farber Cancer InstituteActive, not recruitingRecurrent Head and Neck Carcinoma | Head and Neck Cancer Metastatic | Head or Neck CancerUnited States
-
Royal Marsden NHS Foundation TrustRecruitingRecurrent Head and Neck CancerUnited Kingdom
-
Rakuten Medical, Inc.CompletedRecurrent Head and Neck CancerUnited States
-
University of Colorado, DenverCompletedRecurrent Head and Neck CancerUnited States
-
Chinook Therapeutics, Inc. (formerly Aduro)TerminatedRecurrent Head and Neck Cancer | Metastatic Head and Neck CancerUnited States
-
National Cancer Institute (NCI)TerminatedRecurrent Head and Neck Cancer | Metastatic Head and Neck CancerUnited States
-
AmgenCompletedRecurrent and/or Metastatic Head and Neck Cancer
Clinical Trials on Ad-P53
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI); Department of Health and Human ServicesTerminated
-
Shenzhen SiBiono GeneTech Co.,LtdUnknownAdvanced Oral and Maxillofacial Malignant TumorsChina
-
Shenzhen SiBiono GeneTech Co.,LtdUnknown
-
National Cancer Institute (NCI)CompletedRecurrent Bladder Cancer | Stage III Bladder Cancer | Stage IV Bladder Cancer | Transitional Cell Carcinoma of the Bladder | Stage I Bladder Cancer | Stage II Bladder CancerUnited States
-
Affiliated Hospital of Jiangnan UniversityCompleted
-
Addpharma Inc.CompletedHypertensionKorea, Republic of
-
Addpharma Inc.Recruiting
-
Addpharma Inc.Not yet recruitingHypertension,Essential
-
Shenzhen SiBiono GeneTech Co.,LtdUnknownHCC | DiabetesChina
-
National Cancer Institute (NCI)CompletedLip and Oral Cavity Cancer | Oropharyngeal Cancer | Tongue Cancer | Stage 0 Lip and Oral Cavity Cancer | Stage 0 Oropharyngeal CancerUnited States